These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38303259)

  • 21. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer.
    Urschel JD; Vasan H; Blewett CJ
    Am J Surg; 2002 Mar; 183(3):274-9. PubMed ID: 11943125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus.
    Chao YK; Chan SC; Chang HK; Liu YH; Wu YC; Hsieh MJ; Tseng CK; Liu HP
    Eur J Surg Oncol; 2009 Mar; 35(3):289-94. PubMed ID: 18396384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
    Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
    Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
    Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
    Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effectiveness of planned esophagectomy after neoadjuvant chemoradiotherapy for advanced esophageal carcinomas.
    Kato H; Fukuchi M; Manda R; Faried A; Takita J; Nakajima M; Miyazaki T; Sohda M; Fukai Y; Masuda N; Tsukada K; Kuwano H
    Anticancer Res; 2004; 24(6):4091-6. PubMed ID: 15736457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma.
    Ito R; Nakamura Y; Sunakawa H; Fujiwara H; Hojo H; Nakamura N; Fujita T; Yano T; Daiko H; Akimoto T; Yoshino T; Kojima T
    Esophagus; 2022 Oct; 19(4):645-652. PubMed ID: 35900683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: a monocentric study.
    Schena M; La Rovere E; Solerio D; Bustreo S; Barone C; Daniele L; Buffoni L; Bironzo P; Sapino A; Gasparri G; Ciuffreda L; Ricardi U
    Tumori; 2012; 98(4):451-7. PubMed ID: 23052161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)].
    Schmidt T; Sisic L; Sterzing F; Haag GM; Kunzmann R; Grenacher L; Weichert W; Jäger D; Büchler MW; Ott K
    Chirurg; 2015 Oct; 86(10):955-62. PubMed ID: 25715974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The treatment efficacy and prognosis of each treatment in early postoperative recurrence of esophageal squamous cell carcinoma.
    Ohsawa M; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Hirohata R; Kitasaki N; Okada M
    Surg Today; 2024 Jan; 54(1):53-63. PubMed ID: 37225930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of recurrent disease after neoadjuvant chemoradiotherapy and esophageal cancer surgery with curative intent in a tertiary referral center.
    Schuring N; Stam WT; Plat VD; Kalff MC; Hulshof MCCM; van Laarhoven HWM; Derks S; van der Peet DL; van Berge Henegouwen MI; Daams F; Gisbertz SS
    Eur J Surg Oncol; 2023 Oct; 49(10):106947. PubMed ID: 37355392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
    Chen J; Yin W; Yao H; Gu W
    Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation field size and dose determine oncologic outcome in esophageal cancer.
    Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
    World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Biomarkers of predicting response to neoadjuvant chemoradiotherapy in esophageal cancer].
    Fu JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):805-10. PubMed ID: 24061981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?
    Meguid RA; Hooker CM; Taylor JT; Kleinberg LR; Cattaneo SM; Sussman MS; Yang SC; Heitmiller RF; Forastiere AA; Brock MV
    J Thorac Cardiovasc Surg; 2009 Dec; 138(6):1309-17. PubMed ID: 19931663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microscopic venous invasion is a predictor of prognosis in patients with esophageal squamous cell carcinoma undergoing ineffective neoadjuvant chemotherapy and surgery.
    Tanishima Y; Takahashi K; Nishikawa K; Ishikawa Y; Yuda M; Tanaka Y; Matsumoto A; Yano F; Eto K
    Esophagus; 2023 Oct; 20(4):651-659. PubMed ID: 37081314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
    Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
    Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.